SYNGR1 and synovial sarcoma: Conversely, genetically predicted PLAU (OR 1.77, 95% CI 1.40–2.24), FAM167A (OR 1.20, 95% CI 1.11–1.30), MIF4GD (OR 1.41, 95% CI 1.18–1.69), and SYNGR1 (OR 1.21, 95% CI 1.10–1.33) were positively associated with SS risk (Figure 3).